Association of Statin Use and Mortality After Transcatheter Aortic Valve Replacement

Poghni A. Peri-Okonny, Yangbo Liu, S Chris Malaisrie, Chetan P. Huded, Samir Kapadia, Vinod H. Thourani, Susheel K. Kodali, John Webb, Thomas C. McAndrew, Martin B. Leon, David J. Cohen, Suzanne V. Arnold

Research output: Contribution to journalArticle

Abstract

Background: Statins may reduce mortality after transcatheter aortic valve replacement (TAVR) through prevention of atherosclerotic events or pleiotropic effects. However, the competing mortality risks in TAVR patients may dilute any positive effect of statins. We sought to understand the association of statin use with post-TAVR mortality. Methods and Results: We included high– or intermediate–surgical risk patients who underwent TAVR as a part of the PARTNER (Placement of Aortic Transcatheter Valves) II and Sapien 3 trials and registries. Outcomes included 2-year all-cause, cardiovascular, and noncardiovascular mortality. We used propensity score matching to generate matched pairs between those discharged on a statin and those not on a statin after TAVR. Bias was explored with falsification end points (urinary infection, hip fracture). Among 3956 patients who underwent TAVR, we matched 626 patients on a statin with 626 patients not on a statin at discharge. Among matched patients, statin use was associated with lower risk of all-cause (hazard ratio [HR] 0.65, 95% CI 0.49-0.87, P=0.001), cardiovascular (HR 0.66, 95% CI 0.46-0.96, P=0.030), and noncardiovascular mortality (HR 0.64, 95% CI 0.44-0.99, P=0.045) compared with no statin use. The survival curves diverged within 3 months and continued to separate over a median follow-up of 2.1 years. The falsification end points were similar among groups (urinary infection, P=0.66; hip fracture, P=0.64). Conclusions: In an observational, propensity-matched analysis of TAVR patients, statin use was associated with lower rates of cardiovascular and noncardiovascular mortality compared with no statin use. Given the early emergence of the apparent protective effect of statins, this result may be driven either by pleiotropic effects or by residual confounding despite propensity-matching methodology.

Original languageEnglish (US)
Article numbere011529
JournalJournal of the American Heart Association
Volume8
Issue number8
DOIs
StatePublished - Apr 16 2019

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mortality
Hip Fractures
Transcatheter Aortic Valve Replacement
Propensity Score
Infection
Aortic Valve
Registries

Keywords

  • aortic stenosis
  • outcome
  • statin therapy
  • transcutaneous aortic valve implantation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Peri-Okonny, Poghni A. ; Liu, Yangbo ; Malaisrie, S Chris ; Huded, Chetan P. ; Kapadia, Samir ; Thourani, Vinod H. ; Kodali, Susheel K. ; Webb, John ; McAndrew, Thomas C. ; Leon, Martin B. ; Cohen, David J. ; Arnold, Suzanne V. / Association of Statin Use and Mortality After Transcatheter Aortic Valve Replacement. In: Journal of the American Heart Association. 2019 ; Vol. 8, No. 8.
@article{4a25408ab4dc46afa26bfa594de6cd94,
title = "Association of Statin Use and Mortality After Transcatheter Aortic Valve Replacement",
abstract = "Background: Statins may reduce mortality after transcatheter aortic valve replacement (TAVR) through prevention of atherosclerotic events or pleiotropic effects. However, the competing mortality risks in TAVR patients may dilute any positive effect of statins. We sought to understand the association of statin use with post-TAVR mortality. Methods and Results: We included high– or intermediate–surgical risk patients who underwent TAVR as a part of the PARTNER (Placement of Aortic Transcatheter Valves) II and Sapien 3 trials and registries. Outcomes included 2-year all-cause, cardiovascular, and noncardiovascular mortality. We used propensity score matching to generate matched pairs between those discharged on a statin and those not on a statin after TAVR. Bias was explored with falsification end points (urinary infection, hip fracture). Among 3956 patients who underwent TAVR, we matched 626 patients on a statin with 626 patients not on a statin at discharge. Among matched patients, statin use was associated with lower risk of all-cause (hazard ratio [HR] 0.65, 95{\%} CI 0.49-0.87, P=0.001), cardiovascular (HR 0.66, 95{\%} CI 0.46-0.96, P=0.030), and noncardiovascular mortality (HR 0.64, 95{\%} CI 0.44-0.99, P=0.045) compared with no statin use. The survival curves diverged within 3 months and continued to separate over a median follow-up of 2.1 years. The falsification end points were similar among groups (urinary infection, P=0.66; hip fracture, P=0.64). Conclusions: In an observational, propensity-matched analysis of TAVR patients, statin use was associated with lower rates of cardiovascular and noncardiovascular mortality compared with no statin use. Given the early emergence of the apparent protective effect of statins, this result may be driven either by pleiotropic effects or by residual confounding despite propensity-matching methodology.",
keywords = "aortic stenosis, outcome, statin therapy, transcutaneous aortic valve implantation",
author = "Peri-Okonny, {Poghni A.} and Yangbo Liu and Malaisrie, {S Chris} and Huded, {Chetan P.} and Samir Kapadia and Thourani, {Vinod H.} and Kodali, {Susheel K.} and John Webb and McAndrew, {Thomas C.} and Leon, {Martin B.} and Cohen, {David J.} and Arnold, {Suzanne V.}",
year = "2019",
month = "4",
day = "16",
doi = "10.1161/JAHA.118.011529",
language = "English (US)",
volume = "8",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "8",

}

Peri-Okonny, PA, Liu, Y, Malaisrie, SC, Huded, CP, Kapadia, S, Thourani, VH, Kodali, SK, Webb, J, McAndrew, TC, Leon, MB, Cohen, DJ & Arnold, SV 2019, 'Association of Statin Use and Mortality After Transcatheter Aortic Valve Replacement', Journal of the American Heart Association, vol. 8, no. 8, e011529. https://doi.org/10.1161/JAHA.118.011529

Association of Statin Use and Mortality After Transcatheter Aortic Valve Replacement. / Peri-Okonny, Poghni A.; Liu, Yangbo; Malaisrie, S Chris; Huded, Chetan P.; Kapadia, Samir; Thourani, Vinod H.; Kodali, Susheel K.; Webb, John; McAndrew, Thomas C.; Leon, Martin B.; Cohen, David J.; Arnold, Suzanne V.

In: Journal of the American Heart Association, Vol. 8, No. 8, e011529, 16.04.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association of Statin Use and Mortality After Transcatheter Aortic Valve Replacement

AU - Peri-Okonny, Poghni A.

AU - Liu, Yangbo

AU - Malaisrie, S Chris

AU - Huded, Chetan P.

AU - Kapadia, Samir

AU - Thourani, Vinod H.

AU - Kodali, Susheel K.

AU - Webb, John

AU - McAndrew, Thomas C.

AU - Leon, Martin B.

AU - Cohen, David J.

AU - Arnold, Suzanne V.

PY - 2019/4/16

Y1 - 2019/4/16

N2 - Background: Statins may reduce mortality after transcatheter aortic valve replacement (TAVR) through prevention of atherosclerotic events or pleiotropic effects. However, the competing mortality risks in TAVR patients may dilute any positive effect of statins. We sought to understand the association of statin use with post-TAVR mortality. Methods and Results: We included high– or intermediate–surgical risk patients who underwent TAVR as a part of the PARTNER (Placement of Aortic Transcatheter Valves) II and Sapien 3 trials and registries. Outcomes included 2-year all-cause, cardiovascular, and noncardiovascular mortality. We used propensity score matching to generate matched pairs between those discharged on a statin and those not on a statin after TAVR. Bias was explored with falsification end points (urinary infection, hip fracture). Among 3956 patients who underwent TAVR, we matched 626 patients on a statin with 626 patients not on a statin at discharge. Among matched patients, statin use was associated with lower risk of all-cause (hazard ratio [HR] 0.65, 95% CI 0.49-0.87, P=0.001), cardiovascular (HR 0.66, 95% CI 0.46-0.96, P=0.030), and noncardiovascular mortality (HR 0.64, 95% CI 0.44-0.99, P=0.045) compared with no statin use. The survival curves diverged within 3 months and continued to separate over a median follow-up of 2.1 years. The falsification end points were similar among groups (urinary infection, P=0.66; hip fracture, P=0.64). Conclusions: In an observational, propensity-matched analysis of TAVR patients, statin use was associated with lower rates of cardiovascular and noncardiovascular mortality compared with no statin use. Given the early emergence of the apparent protective effect of statins, this result may be driven either by pleiotropic effects or by residual confounding despite propensity-matching methodology.

AB - Background: Statins may reduce mortality after transcatheter aortic valve replacement (TAVR) through prevention of atherosclerotic events or pleiotropic effects. However, the competing mortality risks in TAVR patients may dilute any positive effect of statins. We sought to understand the association of statin use with post-TAVR mortality. Methods and Results: We included high– or intermediate–surgical risk patients who underwent TAVR as a part of the PARTNER (Placement of Aortic Transcatheter Valves) II and Sapien 3 trials and registries. Outcomes included 2-year all-cause, cardiovascular, and noncardiovascular mortality. We used propensity score matching to generate matched pairs between those discharged on a statin and those not on a statin after TAVR. Bias was explored with falsification end points (urinary infection, hip fracture). Among 3956 patients who underwent TAVR, we matched 626 patients on a statin with 626 patients not on a statin at discharge. Among matched patients, statin use was associated with lower risk of all-cause (hazard ratio [HR] 0.65, 95% CI 0.49-0.87, P=0.001), cardiovascular (HR 0.66, 95% CI 0.46-0.96, P=0.030), and noncardiovascular mortality (HR 0.64, 95% CI 0.44-0.99, P=0.045) compared with no statin use. The survival curves diverged within 3 months and continued to separate over a median follow-up of 2.1 years. The falsification end points were similar among groups (urinary infection, P=0.66; hip fracture, P=0.64). Conclusions: In an observational, propensity-matched analysis of TAVR patients, statin use was associated with lower rates of cardiovascular and noncardiovascular mortality compared with no statin use. Given the early emergence of the apparent protective effect of statins, this result may be driven either by pleiotropic effects or by residual confounding despite propensity-matching methodology.

KW - aortic stenosis

KW - outcome

KW - statin therapy

KW - transcutaneous aortic valve implantation

UR - http://www.scopus.com/inward/record.url?scp=85064320710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064320710&partnerID=8YFLogxK

U2 - 10.1161/JAHA.118.011529

DO - 10.1161/JAHA.118.011529

M3 - Article

VL - 8

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 8

M1 - e011529

ER -